Chronic treatment with olanzapine increases adiposity by changing fuel substrate and causes desensitization of the acute metabolic side effects. (Q54662194)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Chronic treatment with olanzapine increases adiposity by changing fuel substrate and causes desensitization of the acute metabolic side effects.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/24190543

Chronic treatment with olanzapine increases adiposity by changing fuel substrate and causes desensitization of the acute metabolic side effects. (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/24190543

desensitization

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/24190543

Andries Kalsbeek

8

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/24190543

7

object named as

Eric Fliers

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/24190543

Anneke Alkemade

3

object named as

Anneke Alkemade

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/24190543

author name string

Elodie M Girault

1

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/24190543

Ewout Foppen

4

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/24190543

Mariëtte T Ackermans

5

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/24190543

Susanne E la Fleur

6

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/24190543

publication date

5 November 2013

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/24190543

Naunyn-Schmiedeberg's Archives of Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/24190543

387

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/24190543

2

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/24190543

185-195

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/24190543

A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1007%2FS00210-013-0933-5

21 January 2018

Pharmacokinetics and tissue distribution of olanzapine in rats

1 reference

https://api.crossref.org/works/10.1007%2FS00210-013-0933-5

21 January 2018

Olanzapine-associated hypothermia

1 reference

https://api.crossref.org/works/10.1007%2FS00210-013-0933-5

21 January 2018

Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats.

1 reference

https://api.crossref.org/works/10.1007%2FS00210-013-0933-5

21 January 2018

Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration

1 reference

https://api.crossref.org/works/10.1007%2FS00210-013-0933-5

21 January 2018

Insulin resistance following continuous, chronic olanzapine treatment: an animal model

1 reference

https://api.crossref.org/works/10.1007%2FS00210-013-0933-5

21 January 2018

A parametric analysis of olanzapine-induced weight gain in female rats

1 reference

https://api.crossref.org/works/10.1007%2FS00210-013-0933-5

21 January 2018

Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters

1 reference

https://api.crossref.org/works/10.1007%2FS00210-013-0933-5

21 January 2018

Olanzapine causes hypothermia, inactivity, a deranged feeding pattern and weight gain in female Wistar rats

1 reference

https://api.crossref.org/works/10.1007%2FS00210-013-0933-5

21 January 2018

Acute peripheral but not central administration of olanzapine induces hyperglycemia associated with hepatic and extra-hepatic insulin resistance

1 reference

https://api.crossref.org/works/10.1007%2FS00210-013-0933-5

21 January 2018

Sex-specific differences in side effects of psychotropic drugs: genes or gender?

1 reference

https://api.crossref.org/works/10.1007%2FS00210-013-0933-5

21 January 2018

Repeated episodes of hypothermia in a subject treated with haloperidol, levomepromazine, olanzapine, and thioridazine

1 reference

https://api.crossref.org/works/10.1007%2FS00210-013-0933-5

21 January 2018

Are females at special risk of obesity if they become psychotic? The longitudinal Northern Finland 1966 Birth Cohort Study

1 reference

https://api.crossref.org/works/10.1007%2FS00210-013-0933-5

21 January 2018

Plasma leptin and adiposity during antipsychotic treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS00210-013-0933-5

21 January 2018

Palatability, food intake and the behavioural satiety sequence in male rats

1 reference

https://api.crossref.org/works/10.1007%2FS00210-013-0933-5

21 January 2018

Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy

1 reference

https://api.crossref.org/works/10.1007%2FS00210-013-0933-5

21 January 2018

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS00210-013-0933-5

21 January 2018

Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB1-antagonist AVE1625.

1 reference

https://api.crossref.org/works/10.1007%2FS00210-013-0933-5

21 January 2018

Neurobehavioral and metabolic long-term consequences of neonatal maternal deprivation stress and adolescent olanzapine treatment in male and female rats

1 reference

https://api.crossref.org/works/10.1007%2FS00210-013-0933-5

21 January 2018

Weight gain associated with psychotropic drugs

1 reference

https://api.crossref.org/works/10.1007%2FS00210-013-0933-5

21 January 2018

Atypical antipsychotic medications increase postprandial triglyceride and glucose levels in male rats: relationship with stearoyl-CoA desaturase activity

1 reference

https://api.crossref.org/works/10.1007%2FS00210-013-0933-5

21 January 2018

Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration

1 reference

https://api.crossref.org/works/10.1007%2FS00210-013-0933-5

21 January 2018

Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles

1 reference

https://api.crossref.org/works/10.1007%2FS00210-013-0933-5

21 January 2018

Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats

1 reference

https://api.crossref.org/works/10.1007%2FS00210-013-0933-5

21 January 2018

Chronic treatment with olanzapine via a novel infusion pump induces adiposity in male rats.

1 reference

https://api.crossref.org/works/10.1007%2FS00210-013-0933-5

21 January 2018

Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat.

1 reference

https://api.crossref.org/works/10.1007%2FS00210-013-0933-5

21 January 2018

The role of thermogenesis in antipsychotic drug-induced weight gain.

1 reference

https://api.crossref.org/works/10.1007%2FS00210-013-0933-5

21 January 2018

Negative effects of chronic oral chlorpromazine and olanzapine treatment on the performance of tasks designed to assess spatial learning and working memory in rats

1 reference

https://api.crossref.org/works/10.1007%2FS00210-013-0933-5

21 January 2018

Olanzapine-induced weight gain: chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution

1 reference

https://api.crossref.org/works/10.1007%2FS00210-013-0933-5

21 January 2018

Olanzapine affects locomotor activity and meal size in male rats

1 reference

https://api.crossref.org/works/10.1007%2FS00210-013-0933-5

21 January 2018

Effect of treatment on weight gain and metabolic abnormalities in patients with first-episode psychosis

1 reference

https://api.crossref.org/works/10.1007%2FS00210-013-0933-5

21 January 2018

Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain

1 reference

https://api.crossref.org/works/10.1007%2FS00210-013-0933-5

21 January 2018

Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone

1 reference

https://pubmed.ncbi.nlm.nih.gov/24190543

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24190543

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The quantification of gluconeogenesis in healthy men by (2)H2O and [2-(13)C]glycerol yields different results: rates of gluconeogenesis in healthy men measured with (2)H2O are higher than those measured with [2-(13)C]glycerol

1 reference

https://pubmed.ncbi.nlm.nih.gov/24190543

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys

1 reference

https://pubmed.ncbi.nlm.nih.gov/24190543

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Atypical antipsychotics rapidly and inappropriately switch peripheral fuel utilization to lipids, impairing metabolic flexibility in rodents

1 reference

https://pubmed.ncbi.nlm.nih.gov/24190543

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Olanzapine causes a leptin-dependent increase in acetylcholine release in mouse prefrontal cortex.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24190543

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influences of glucose loading and of injected insulin on hepatic glucose output

1 reference

https://pubmed.ncbi.nlm.nih.gov/24190543

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clozapine and weight gain.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24190543

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects

1 reference

https://pubmed.ncbi.nlm.nih.gov/24190543

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hypothermia induced by risperidone and olanzapine in a patient with Prader-Willi syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/24190543

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Differences between men and women in side effects of second-generation antipsychotics]

1 reference

https://pubmed.ncbi.nlm.nih.gov/24190543

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Atypical antipsychotics and weight gain in Chinese patients: a comparison of olanzapine and risperidone.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24190543

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat

1 reference

https://pubmed.ncbi.nlm.nih.gov/24190543

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00210-013-0933-5

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/24190543

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/24190543

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54662194&oldid=2212553941"